# EGFR new study: Grb2 phosphorylation and Ras

> A 2026 PLoS ONE paper on Grb2 phosphorylation and EGFR condensates, placed in context with DepMap, ChEMBL, Open Targets and CIViC data as of 2026-11-06.

Data as of 2026-11-06 · Published 2026-11-07 · Updated 2026-11-06 · https://bioq.bio/blog/en/egfr-grb2-phosphorylation-antagonizes-egfr-driven-ras-activation-by-interf

![BioQ result page for the query EGFR, showing the answer with named sources for dependency, drugs and disease association.](https://bioq.bio/blog/img/egfr-grb2-phosphorylation-antagonizes-egfr-driven-ras-activation-by-interf/en/hero.webp)

A new study in PLoS ONE (2026) examines how kinase activity at EGFR, Grb2 phosphorylation and condensate assembly shape signal output to Ras. BioQ's data give the surrounding context: in DepMap, EGFR is a dependency in 224 of 1178 cell lines (19.0%), and it is not common essential. The data are as of 2026-11-06, and the paper's own results belong to the paper, not to BioQ.

## What we asked: a new study on EGFR and Grb2

The paper uses a reconstituted system to ask how changing EGFR kinase activity alters signal flow through Grb2 and SOS to Ras. Grb2 phosphorylation appears as a feedback step that can disrupt condensate formation. The authors discuss how this bears on tyrosine kinase inhibition. We do not restate their experiments or conclusions here. Read the paper (DOI 10.1371/journal.pone.0361303) for those.

BioQ does not hold reconstitution data, so it cannot test or confirm the paper's mechanism. It can answer a narrower question: what do public data layers say today about EGFR itself? We asked for dependency, known drugs, disease association, variant evidence, expression, pathways and interaction partners. The query was the single word EGFR.

## What BioQ returned

One query drew on 7 distinct resources through 7 engine queries, which took 1.65 engine seconds in total. Each block below names its source.

**Dependency (DepMap, Chronos).** Across 1178 cell lines the mean gene effect is -0.294. A more negative value means the knockout reduced viability more. The strongest lineages are these:

| Lineage | Cell lines | Dependent | % dependent | Mean gene effect |
|---|---|---|---|---|
| Head and Neck | 77 | 51 | 66.2 | -0.702 |
| Prostate | 10 | 6 | 60 | -0.696 |
| Biliary Tract | 35 | 17 | 48.6 | -0.561 |
| Cervix | 18 | 7 | 38.9 | -0.434 |
| Esophagus/Stomach | 69 | 27 | 39.1 | -0.422 |
| Liver | 24 | 6 | 25 | -0.406 |
| Bowel | 63 | 21 | 33.3 | -0.399 |
| Bladder/Urinary Tract | 34 | 10 | 29.4 | -0.39 |

![BioQ screenshot of the DepMap Chronos dependency view for EGFR by cancer lineage](https://bioq.bio/blog/img/egfr-grb2-phosphorylation-antagonizes-egfr-driven-ras-activation-by-interf/en/dep.webp)
*DepMap Chronos gene effect for EGFR by lineage, as returned by BioQ.*

**Drugs (Open Targets, ChEMBL, Drug Repurposing Hub, ClinicalTrials.gov).** BioQ lists 118 drugs for EGFR. The table shows 8 of them, with the exact IC50-based pChEMBL value where one exists. Higher pChEMBL means stronger potency.

| Drug | Max clinical stage | Mechanism | Best exact pChEMBL | Type | Trials by name |
|---|---|---|---|---|---|
| Osimertinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 11.7 | IC50 | 188 |
| Afatinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 11 | IC50 | 112 |
| Mobocertinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 11 | IC50 | 4 |
| Neratinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 10.7 | IC50 | 69 |
| Erlotinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 10.54 | IC50 | 355 |
| Lapatinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 10.22 | IC50 | 144 |
| Gefitinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 10 | IC50 | 214 |
| Aumolertinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 9.74 | IC50 | 11 |

**Disease association (Open Targets).** EGFR is linked to 5943 diseases. The top of the list is:

| Disease | Association score | Evidence items |
|---|---|---|
| non-small cell lung carcinoma | 0.847 | 30752 |
| lung adenocarcinoma | 0.775 | 8408 |
| cancer | 0.735 | 25216 |
| head and neck squamous cell carcinoma | 0.725 | 3440 |
| lung cancer | 0.718 | 13799 |
| breast cancer | 0.682 | 9636 |

**Other layers.** CIViC holds 286 clinical evidence records for EGFR. The top five shown are all in Lung Non-small Cell Carcinoma. They include EGFR L858R with Gefitinib and Erlotinib (level B, Sensitivity/Response). They also include EGFR T790M with Erlotinib (level A, Resistance). Reactome lists 74 pathways for EGFR, among them Inhibition of Signaling by Overexpressed EGFR (R-HSA-5638303, 8 genes). In TCGA/GTEx Toil data, 24 cancer types have both tumour and normal samples. Glioblastoma Multiforme shows a log2 fold of 0.46 (153 tumours, 5 normals), and Breast Invasive Carcinoma shows -0.4 (1092 tumours, 113 normals). STRING v12 reports 5820 interaction partners. The six shown, DCN, HBEGF, EREG, CDH1, GAB1 and PIK3CA, all score 999.

## What it means and how to read it

The paper concerns the signaling chain from activated EGFR through Grb2 and SOS to Ras. The BioQ data sit around that chain and do not describe it. Three readings are useful.

First, dependency is uneven. EGFR is not common essential, and dependency concentrates in particular lineages. Head and Neck shows 51 of 77 lines dependent (66.2%), and Prostate shows 6 of 10 (60.0%). The Prostate group is small, so treat that percentage with care. A paper on EGFR signaling mechanics may hold in a reconstituted system, but DepMap tells you where cell viability actually leans on the receptor.

Second, the drug landscape is dense. All 8 drugs shown carry the maximum clinical stage APPROVAL and the same mechanism label. Their exact IC50 pChEMBL values run from 11.7 for Osimertinib to 9.74 for Aumolertinib. The paper's topic is how kinase inhibition can have non-obvious effects on Ras output in a defined system. The potency values here only say how strongly each compound inhibits the enzyme in ChEMBL assays. They say nothing about the cellular feedback the paper examines.

Third, the network context is consistent. GAB1 and PIK3CA appear among the top STRING partners, which fits EGFR's place in downstream signaling. GRB2 is not among the six shown. That reflects only the ranking and the display limit, not an absence of the interaction. To check it, run a direct query for the EGFR and GRB2 pair.

Expression adds a caution. Tumour mRNA levels vary in direction by cancer type, with some types above normal and others below. mRNA says nothing about phosphorylation state or condensation, which is what the paper is about.

## How to reproduce it in BioQ

1. Open BioQ and make sure the query box is empty.
2. Enter the query below exactly.

```text
EGFR
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3DEGFR)

3. Read the dependency, drug and disease blocks first. Each block names its source and release.
4. To follow the paper's theme, ask a second query about the GRB2 interaction with EGFR and compare the partner scores.
5. Note the data date in the answer (2026-11-06) if you cite it.

The manual route would mean visiting DepMap, ChEMBL, Open Targets, CIViC, TCGA/GTEx, Reactome and STRING separately and aligning gene identifiers across them. BioQ returned these 7 resources in 1.65 engine seconds. That figure covers the engine time only, not your reading time.

## Limits: what the data do not show

- BioQ does not contain the paper's data. It cannot confirm, refute or quantify its findings on Grb2 phosphorylation, condensate assembly or Ras activation.
- DepMap measures CRISPR knockout effects in cell lines. It does not model acute kinase inhibition, feedback loops or condensates. A dependency here is defined by a named threshold, not by a property of the biology.
- pChEMBL values come from varied assays and say nothing about cellular outcomes, including the context-dependent effects the paper discusses.
- Open Targets scores and evidence counts measure the amount of supporting evidence, not its direction or clinical meaning.
- The CIViC, trial and drug listings are records of the literature. They give no guidance on treatment.
- The tables show only the top rows of much longer lists.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-06 (7 queries, 1.6 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/civic`, `/depmap`, `/drugs`, `/interaction`, `/ot_association`, `/pathway`, `/tcga`

## Sources
- Grb2 phosphorylation antagonizes EGFR-driven ras activation by interfering with condensate assembly (2026) — [doi:10.1371/journal.pone.0361303](https://doi.org/10.1371/journal.pone.0361303)

Run the same query yourself: [EGFR](https://bioq.bio/login?next=%2Fapp%23q%3DEGFR)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`EGFR`](https://bioq.bio/login?next=%2Fapp%23q%3DEGFR)

## Frequently asked questions

### Is EGFR a common essential gene in DepMap?

No. DepMap marks EGFR as not common essential. It is a dependency in 224 of 1178 cell lines (19.0%), with a mean Chronos gene effect of -0.294.

### Which cancer lineages depend most on EGFR in DepMap?

Head and Neck leads, with 51 of 77 lines dependent (66.2%) and a mean gene effect of -0.702. Prostate follows at 6 of 10 lines (60.0%), but that group is small.

### How many EGFR inhibitors does BioQ list, and how potent are they?

BioQ lists 118 drugs for EGFR. Among the 8 shown, exact IC50 pChEMBL values run from 11.7 for Osimertinib to 9.74 for Aumolertinib.

### Which disease is most associated with EGFR in Open Targets?

Non-small cell lung carcinoma has the top association score of 0.847, with 30752 evidence items. EGFR is linked to 5943 diseases in total.

### Does BioQ confirm the Grb2 phosphorylation findings?

No. The paper's results are the paper's own. BioQ shows public context for EGFR, such as dependency, drugs and pathways, and holds no reconstitution data on Grb2 or condensates.

## Sources

- Paper: [Grb2 phosphorylation antagonizes EGFR-driven ras activation by interfering with condensate assembly](https://doi.org/10.1371/journal.pone.0361303) (2026) DOI 10.1371/journal.pone.0361303
- Dataset: [DepMap CRISPR Chronos gene effect (24Q4)](https://depmap.org/portal/)
- Dataset: [Open Targets Platform; ChEMBL; Drug Repurposing Hub](https://platform.opentargets.org/)
- Dataset: [TCGA pan-cancer expression (UCSC Xena Toil recompute)](https://xenabrowser.net/)
- Dataset: [CIViC: Clinical Interpretation of Variants in Cancer](https://civicdb.org/)
- Dataset: [Reactome pathway knowledgebase](https://reactome.org/)
- Dataset: [STRING v12 protein-protein interactions](https://string-db.org/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
